RxDoctor Payments Data

Mohammadali Habibi, MD

Cardiology · Baltimore, MDNPI 1417274820

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (39.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 65.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $8,130 and has fallen 83.3% since, to $1,355 in 2025. Among cardiology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,623in general payments, 2019–2025

Across 115 payments — averaging $127.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Abbott$2K
  • Biotronik Inc.$1K
  • Boston Scientific$989
  • Philips North America LLC$426
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$310
  • plus $475 from 7 others

What the payments were for

  • Grants$5,83340%
  • Travel & lodging$2,66718%
  • Food & beverage$5,30936%
  • Education$8146%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,623 in reported general payments places this provider in the 95th percentile of 44 cardiology providers in Maryland.

See all cardiology providers in Maryland

Medicare billing

Part B allowed, 2024
$496,751
Medicare patients
640
Services billed
4,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$151,013
XareltoRivaroxaban59$63,205
MultaqDronedarone Hcl17$30,106
EntrestoSacubitril/Valsartan11$11,481
Metoprolol Succinate101$1,432
Flecainide Acetate24$1,386
Amiodarone Hcl41$806
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$347
Losartan Potassium17$241
Metoprolol Tartrate18$129
Carvedilol11$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCMultaq$29$30,10617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 44 cardiology providers in Maryland.

Other cardiology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →